TY - JOUR
T1 - Frailty and subsequent adverse outcomes in older patients with atrial fibrillation treated with oral anticoagulants
T2 - The Shizuoka study
AU - Nishimura, Shiori
AU - Kumamaru, Hiraku
AU - Shoji, Satoshi
AU - Nakatani, Eiji
AU - Yamamoto, Hiroyuki
AU - Ichihara, Nao
AU - Sandhu, Alexander T.
AU - Miyachi, Yoshiki
AU - Miyata, Hiroaki
AU - Kohsaka, Shun
N1 - Funding Information:
S.K. reports the receipt of an investigator-initiated grant from Novartis. H.K. has received consultation fees from Mitsubishi Tanabe Pharma and speaker’s fees from Pfizer Japan Inc and Johnson & Johnson K.K.. H.Y. has received consultation fees from Mitsubishi Tanabe Pharma, speaker’s fees from Chugai Pharmaceutical Co Ltd and Ono Pharmaceutical Co Ltd, and payment for a manuscript from Astellas Pharma Inc. H.M. has received a research grant from AstraZeneca K.K. for an independent research project through the PeoPLe Consortium at Keio University. S.K., H.K., S.N., N.I., H.Y., and H.M. are affiliated with the Department of Healthcare Quality Assessment at The University of Tokyo. This department is a social collaboration department supported by the National Clinical Database, Johnson & Johnson K.K., Nipro Corporation, and Intuitive Surgical Sàrl. The other authors report no potentially conflicting interests.
Funding Information:
The Shizuoka Graduate University of Public Health conducts contract research projects on public health in Shizuoka Prefecture, including this study. The results and conclusions reported in this article are those of the authors and are independent of the funding sources. This study was approved by the Ethics Committee of the Shizuoka Graduate University of Public Health (Shizuoka, Japan) (#SGUPH_2021_001_006). S.K. is the guarantor. S.N, H.K. S.S. and S.K. were involved in concept and design. S.N. H.K. S.S. E.N. A.T.S. Y.M. H.M. and S.K. were involved in acquisition, analysis, or interpretation of data. S.N. H.K. S.S. and S.K. were involved in drafting of the manuscript. E.N. N.I. A.T.S. Y.M. and H.M. were involved in critical revision of the manuscript for important intellectual content. S.N. and H.K. performed the statistical analysis. Y.M. and H.M. supervised the study. All authors participated in the writing of the paper. S.K. reports the receipt of an investigator-initiated grant from Novartis. H.K. has received consultation fees from Mitsubishi Tanabe Pharma and speaker's fees from Pfizer Japan Inc and Johnson & Johnson K.K. H.Y. has received consultation fees from Mitsubishi Tanabe Pharma, speaker's fees from Chugai Pharmaceutical Co Ltd and Ono Pharmaceutical Co Ltd, and payment for a manuscript from Astellas Pharma Inc. H.M. has received a research grant from AstraZeneca K.K. for an independent research project through the PeoPLe Consortium at Keio University. S.K. H.K. S.N. N.I. H.Y. and H.M. are affiliated with the Department of Healthcare Quality Assessment at The University of Tokyo. This department is a social collaboration department supported by the National Clinical Database, Johnson & Johnson K.K. Nipro Corporation, and Intuitive Surgical Sàrl. The other authors report no potentially conflicting interests. Based on the data use agreement with the regional insurers in the prefecture of Shizuoka, we are unable to make the analytical data accessible to readers.
Publisher Copyright:
© 2023 The Authors
PY - 2023/3
Y1 - 2023/3
N2 - Background: In older patients with atrial fibrillation (AF), frailty is frequently prevalent. However, the prognostic value of frailty for adverse events after initiation of oral anticoagulants (OACs) is unclear. Objectives: We assessed whether frailty at the time of OAC initiation is associated with subsequent bleeding or embolic events. Methods: We extracted patients aged ≥65 years with nonvalvular AF in whom OACs were initiated from a universal administrative claims database incorporating primary and hospital care records in Shizuoka, Japan, between 2012 and 2018. Frailty was assessed using the electronic frailty index (eFI). The association of frailty with bleeding events and ischemic stroke/transient ischemic attack were evaluated using the Fine-Gray model and restricted cubic spline model. Results: Among 12,585 patients with AF, 7.8% were categorized as fit, 31.5% as mildly frail, 34.8% as moderately frail, and 25.9% as severely frail. The risk of bleeding was associated with a higher eFI (adjusted subdistribution hazard ratio [95% CI] for fit or mild frailty: 1.15 [1.02-1.30]; moderate frailty: 1.42 [1.24-1.61]; and severe frailty: 1.86 [1.61-2.15]), whereas the association was weaker for ischemic stroke/transient ischemic attack. The spline models demonstrated that the relative hazard for bleeding increased steeply with increasing eFI. Conclusion: Patients with frailty in whom OAC therapy is initiated have higher risk of bleeding, highlighting the importance of discussing this increased risk with patients with AF who have frailty and assessing frailty at the time of OAC initiation.
AB - Background: In older patients with atrial fibrillation (AF), frailty is frequently prevalent. However, the prognostic value of frailty for adverse events after initiation of oral anticoagulants (OACs) is unclear. Objectives: We assessed whether frailty at the time of OAC initiation is associated with subsequent bleeding or embolic events. Methods: We extracted patients aged ≥65 years with nonvalvular AF in whom OACs were initiated from a universal administrative claims database incorporating primary and hospital care records in Shizuoka, Japan, between 2012 and 2018. Frailty was assessed using the electronic frailty index (eFI). The association of frailty with bleeding events and ischemic stroke/transient ischemic attack were evaluated using the Fine-Gray model and restricted cubic spline model. Results: Among 12,585 patients with AF, 7.8% were categorized as fit, 31.5% as mildly frail, 34.8% as moderately frail, and 25.9% as severely frail. The risk of bleeding was associated with a higher eFI (adjusted subdistribution hazard ratio [95% CI] for fit or mild frailty: 1.15 [1.02-1.30]; moderate frailty: 1.42 [1.24-1.61]; and severe frailty: 1.86 [1.61-2.15]), whereas the association was weaker for ischemic stroke/transient ischemic attack. The spline models demonstrated that the relative hazard for bleeding increased steeply with increasing eFI. Conclusion: Patients with frailty in whom OAC therapy is initiated have higher risk of bleeding, highlighting the importance of discussing this increased risk with patients with AF who have frailty and assessing frailty at the time of OAC initiation.
KW - anticoagulants
KW - atrial fibrillation
KW - frailty
KW - hemorrhage
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=85153610766&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85153610766&partnerID=8YFLogxK
U2 - 10.1016/j.rpth.2023.100129
DO - 10.1016/j.rpth.2023.100129
M3 - Article
AN - SCOPUS:85153610766
SN - 2475-0379
VL - 7
JO - Research and Practice in Thrombosis and Haemostasis
JF - Research and Practice in Thrombosis and Haemostasis
IS - 3
M1 - 100129
ER -